NCT07193134View on ClinicalTrials.gov

GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2035

Conditions
RDEBRecessive Dystrophic Epidermolysis BullosaEpidermolysis Bullosa Dystrophica, Recessive
Interventions
DRUG

Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS)

Wound debridement will be performed, followed by the application of temporary allogeneic skin grafts for 3-5 days. The allografts will then be removed, and the GMEB-SASS grafts will be applied.

Trial Locations (1)

M5G 1E8

The Hospital for Sick Children (SickKids), Toronto

All Listed Sponsors
lead

CHU de Quebec-Universite Laval

OTHER

NCT07193134 - GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment | Biotech Hunter | Biotech Hunter